Alkem Labs vs Biocon vs Glenmark Pharma: Which Stock Should You Track

Alkem Laboratories vs Biocon vs Glenmark Pharmaceuticals starts with the core numbers most investors compare within the Pharma and Biotech segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of October 2026 and will shift with daily price moves.

All three names sit in the Pharma and Biotech bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.

Click Here – Get Free Investment Predictions

Alkem Laboratories, Biocon and Glenmark Pharmaceuticals: Company Overview

Alkem Laboratories is a listed Indian company in the Pharma and Biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Biocon is a listed Indian company in the Pharma and Biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Glenmark Pharmaceuticals is a listed Indian company in the Pharma and Biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Alkem Laboratories vs Biocon vs Glenmark Pharmaceuticals: Valuation and Profitability Snapshot

Metric	Alkem Laboratories	Biocon	Glenmark Pharmaceuticals
Market Cap (approx.)	Rs 63,814 crore	Rs 64,234 crore	Rs 67,254 crore
PE Ratio (TTM)	28.95	153.96	37.41
PB Ratio	4.62	1.86	6.40
Return on Equity (ROE)	16.66%	1.14%	28.08%
EPS (TTM, Rs)	184.35	2.56	63.70
Dividend Yield	0.99%	0.13%	0.21%
Debt to Equity	0.15	0.45	0.06
Book Value per Share (Rs)	1155.87	211.51	372.47

Check the Univest Screener for Live Data

On valuation, Alkem Laboratories trades at a PE of 28.95 and a PB of 4.62, Biocon at a PE of 153.96 and a PB of 1.86, while Glenmark Pharmaceuticals trades at a PE of 37.41 and a PB of 6.40. On return on equity, the three post 16.66%, 1.14% and 28.08% respectively, and on dividend yield they stand at 0.99%, 0.13% and 0.21%.

Alkem Laboratories vs Biocon vs Glenmark Pharmaceuticals: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)
Alkem Laboratories	Rs 3,892.90 crore	Rs 521.49 crore	+11.0%	+2.4%
Biocon	Rs 4,390.50 crore	Rs 136.80 crore	+9.2%	-3.9%
Glenmark Pharmaceuticals	Rs 4,084.24 crore	Rs 482.83 crore	+24.1%	+3.1%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter.

Download the Univest iOS App or Univest Android App to track Alkem Laboratories, Biocon and Glenmark Pharmaceuticals live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharma and biotech names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.

Conclusion

Alkem Laboratories vs Biocon vs Glenmark Pharmaceuticals highlights how differently three companies in the same pharma and biotech segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Alkem Laboratories vs Biocon vs Glenmark Pharmaceuticals

What is the market cap difference between Alkem Laboratories, Biocon and Glenmark Pharmaceuticals?

Ans. As of October 2026, Alkem Laboratories has a market cap of approximately Rs 63,814 crore, Biocon is at approximately Rs 64,234 crore, and Glenmark Pharmaceuticals is at approximately Rs 67,254 crore.

Which of the three has the highest PE ratio?

Ans. Among Alkem Laboratories, Biocon and Glenmark Pharmaceuticals, the PE ratios stand at 28.95, 153.96 and 37.41 respectively as of October 2026.

Which of the three has the highest ROE?

Ans. Alkem Laboratories, Biocon and Glenmark Pharmaceuticals post ROE of 16.66%, 1.14% and 28.08% respectively as of October 2026.

Which of these three stocks pays the highest dividend yield?

Ans. Alkem Laboratories, Biocon and Glenmark Pharmaceuticals carry dividend yields of 0.99%, 0.13% and 0.21% respectively.

What is the debt to equity ratio for Alkem Laboratories, Biocon and Glenmark Pharmaceuticals?

Ans. Alkem Laboratories carries a debt to equity of 0.15, Biocon of 0.45, and Glenmark Pharmaceuticals of 0.06.

Which of the three trades at the highest price to book value?

Ans. Alkem Laboratories, Biocon and Glenmark Pharmaceuticals trade at price to book ratios of 4.62, 1.86 and 6.40 respectively.

Is one of Alkem Laboratories, Biocon or Glenmark Pharmaceuticals better than the others?

Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.